A computational disease analysis
for SLC6A1 epilepsy
SLC6A1-related epilepsy is exactly the kind of condition this was built for — rare enough that standard pharma pipelines underinvest, but important enough that the families deserve the same depth of analysis that billion-dollar diseases get.
The PHYSIM Platform: A deterministic computational physics platform. Governed by strict mathematical laws, the system maps the entire human genome across every known disease to compute biological certainty, not generative probability. AI serves only as our translator — the core analysis is reproducible, auditable, and deterministic.
This does not replace the laboratory — it de-risks before you get there. Instead of screening thousands of candidates blindly, the system narrows the search space to a focused set of computationally validated targets worth testing. Each finding on this page is a possible new discovery — a possible path toward helping patients — that deserves rigorous experimental validation.
A complete disease cascade report
The same computational analysis we run for every disease, applied to SLC6A1. No abbreviated version. No demo. The full CDA report.
Complete Gene Cascade Map
How SLC6A1 disruption propagates through connected pathways. Every downstream gene node mapped, ranked by proximity to the disease hub, with evidence grades.
FDA-Approved Compound Screen
A ranked list of existing, FDA-approved or late-stage compounds predicted to engage the SLC6A1 cascade. No novel synthesis required — these are drugs that already exist.
Safety Pre-Screening
Cardiac (hERG) and liver (DILI) safety pre-screening for every candidate compound. No surprises in toxicity — the safety profile is computed before any recommendation.
Novel Pathway Discovery
Any connections the analysis surfaces that are ahead of published literature. These are "Gate B" findings — computationally predicted, not yet validated, potentially publishable.
Rare diseases deserve the same analysis that billion-dollar diseases get
Large pharma invests hundreds of millions in drug screening for cancer, diabetes, cardiovascular disease. Rare diseases like SLC6A1-related epilepsy get a fraction of that attention — not because the biology is less interesting, but because the market is smaller.
PHYSIM runs the same computational engine, the same compound screening, the same safety panels. The only difference is who’s paying attention.
29 disease analyses completed
A selection of diseases we've already run through the engine — each with a full cascade report, compound screening, and safety panels.
The Math Behind the Target Convergence
To establish deterministic parity, we ran a multi-layered structural proximity intersection for SLC6A1 and the GAT-1 Transporter.
"No one should have to fight for answers alone. For the rarest diseases, sometimes science needs to meet a family halfway."
— SLC6A1 Connect, patient advocacy foundation
Commission a Computational Disease Analysis
We produce pre-clinical CDA reports that map your disease of interest across the full human genome — identifying novel pathways, repurposable compounds, and structural drug targets before you enter the lab. Tell us what you’re working on.
Start a Conversation →